At a glance
- Eligibility is confirmed by biomarker and pathology testing first.
- Given on a fixed cycle, as a day-care infusion.
- Immune-related side effects are screened for at every visit.
How immunotherapy works
Cancer cells often hide from the immune system by switching off the T-cells that would attack them. Immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies) release that brake so the immune system can recognise and destroy the cancer.
Who is eligible
Immunotherapy is standard in many cancers — lung, kidney, bladder, melanoma, head and neck, some lymphomas, MSI-high colorectal and gastric cancers, liver and cervical cancer among others. Eligibility depends on biomarkers such as PD-L1 expression or MSI status, which we test before recommending treatment.
Treatment at Shichim
Immunotherapy is given as a short day-care infusion every two to six weeks. Because it can cause immune-related side effects (thyroid, skin, bowel, lungs), we screen for them at every visit and treat them early.